MYLS22

MYLS22 is a selective optic atrophy 1OPA1 inhibitor. MYLS22 reduces tumor vascularization and associated lymphatic angiogenesis by inhibiting OPA1, thereby limiting tumor growth and metastasis and effectively normalizing tumor vascular morphology. MYLS22 has anticancer activity .


Cat. No.: EX-A9296	Purity: >98%

	Chemical structure of MYLS22

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
1g	585	In-stock
5g	1585	In-stock
10g	2885	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	306959-01-3
Purity	>98%
Formula	C24H21N5O2S
Mol Weight	443.521
Appearance	solid
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Larrue C, et al. Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia. Leukemia. 2023 Apr;37(4):765-775. [2]. Schuler MH, et al. OPA1 and Angiogenesis: Beyond the Fusion Function. Cell Metab. 2020 May 5;31(5):886-887. [3]. Herkenne S, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8. [4]. Jiang HL, et al. L-OPA1 deficiency aggravates necroptosis of alveolar epithelial cells through impairing mitochondrial function during acute lung injury in mice. J Cell Physiol. 2022 Jul;237(7):3030-3043.
CoA	CoA of MYLS22

Smiles:	O=C(C(S1)=CC2=C1N(C3=CC=CC=C3)N=C2C)NC4=C(C)N(C)N(C5=CC=CC=C5)C4=O


		Search